Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amur Minerals ( (GB:CRTX) ) has shared an announcement.
CRISM Therapeutics Corporation is set to announce its interim results for the first half of 2025, followed by a live presentation hosted by CEO Andrew Webb. The presentation will feature insights from Professor Garth Cruickshank on the upcoming Phase 2 trial of irinotecan-ChemoSeed for glioblastoma, highlighting the company’s strategic focus on advancing cancer treatment through innovative drug delivery solutions.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage company specializing in drug delivery technology aimed at enhancing cancer treatment effectiveness for solid tumors. Their flagship product, ChemoSeed, allows for localized and sustained chemotherapy drug delivery directly into tumors or resection margins, particularly useful in treating glioblastoma by bypassing the blood-brain barrier.
Average Trading Volume: 61,674
Technical Sentiment Signal: Sell
Current Market Cap: £3.8M
See more data about CRTX stock on TipRanks’ Stock Analysis page.